证券代码：002298 证券简称：中电鑫龙 编号：2025-054 安徽中电鑫龙科技股份有限公司（以下简称"公司"或"本公司"）2025 年第二次独立董事专门会议于 2025 年 8 月 27 日以通讯方式召开。本次会议应出 席独立董事 3 人，实际出席独立董事 3 人，全体独立董事共同推举许礼进先生召 集并主持本次会议。本次独立董事专门会议的召集、召开及表决程序符合《公司 法》、《公司章程》、《独立董事制度》、《独立董事专门会议制度》等有关规 定。 安徽中电鑫龙科技股份有限公司 二○二五年八月二十七日 经审查，全体独立董事认为：本次变更公司员工持股计划部分条款的事项符 合《公司法》《证券法》《关于上市公司实施员工持股计划试点的指导意见》《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关 法律、法规、规范性文件有关规定，已取得了现阶段必要的批准与授权，并履行 了相应的审议程序，符合《试点指导意见》《自律监管指引第 1 号》等有关法 律、法规和规范性文件的规定，不存在损害公司及全体股东利益的情形。因此， 我们同意《关于变更公司员工持股计划部分条款的议案》，并同意提交公司第十 届董事会 ...

证券代码：002298 证券简称：中电鑫龙 编号：2025-051 （一）会议以 3 票同意、0 票反对、0 票弃权的表决结果，审议通过了《2025 年半年度报告及摘要的议案》。 经审核，监事会认为：董事会编制和审议公司 2025 年半年度报告的程序符合 法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 安徽中电鑫龙科技股份有限公司 第十届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 安徽中电鑫龙科技股份有限公司（以下简称"公司"或"本公司"）第十届监 事会第三次会议于 2025 年 8 月 15 日以专人送达、电子邮件、通讯方式向全体监事 发出召开第十届监事会第三次会议的通知。会议于 2025 年 8 月 27 日以现场和通讯 相结合的方式召开。会议应出席监事 3 人，实际出席监事 3 人。会议符合《公司法》 和《公司章程》的有关规定。本次会议由公司监事会主席张廷勇先生主持。 二、监事会会议审议情况 经与会监事表决，通过如下决议： ...

Investment Rating - The report maintains an "Outperform the Market" rating for the company [5][16][20]. Core Views - The company's revenue decreased slightly, with a transition from profit to loss. In H1 2025, the company achieved revenue of 1.295 billion yuan, a year-on-year decline of 8.23%. The net profit attributable to the parent company was -50.5 million yuan, a decrease of 96 million yuan year-on-year, aligning with market expectations [1][3][7]. - The decline in revenue is primarily attributed to the slower-than-expected conversion of new contracts. The gross profit margin fell by 4.11 percentage points to 40.33% [1][3][7]. - The company has 14 ongoing PPP projects, and new regulations from the Ministry of Finance are expected to improve cash flow and reduce impairment burdens [2][12][15]. - The company plans to repurchase shares worth 100-150 million yuan at a price not exceeding 29.5 yuan per share, which is seen as a positive signal for shareholder confidence [2][12][15]. Financial Performance Summary - For H1 2025, the company reported a revenue of 1.295 billion yuan, down 8.23% year-on-year. The revenue from Puyue Technology was 482 million yuan, a decline of 5.9%, accounting for 37% of total revenue [1][7]. - The gross profit margin for the instrument, software, and consumables segment was 44.55%, down 3.77 percentage points year-on-year. The operating service, testing service, and consulting service segment saw a revenue of 213 million yuan, down 11.83%, with a gross profit margin of 35.77%, down 4.03 percentage points [2][12]. - The company expects net profits for 2025-2027 to be 267 million, 344 million, and 415 million yuan, respectively, with year-on-year growth rates of 29.2%, 28.8%, and 20.6% [3][16]. Segment Performance - The revenue from the instrument, related software, and consumables business was 896 million yuan, down 7.39% year-on-year. The environmental equipment and engineering business generated 135 million yuan, down 2.3% [2][12]. Shareholder Confidence - The planned share repurchase is intended to boost shareholder confidence and is indicative of management's positive outlook on the company's future [2][12][15].

证券代码：688222 证券简称：成都先导 公告编号：2025-038 成都先导药物开发股份有限公司 第二届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都先导药物开发股份有限公司（以下简称"公司"）第二届董事会第二十三 次会议于 2025 年 8 月 26 日在公司会议室以现场结合通讯表决方式召开，会议通 知已于 2025 年 8 月 16 日以书面方式送达全体董事。本次会议应出席董事 9 名， 实际出席董事 9 名，公司监事、董事会秘书和部分高级管理人员列席本次会议， 会议由董事长 JIN LI（李进）先生召集并主持。本次会议的召集和召开程序符合 有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，会议决议 合法、有效。 二、董事会会议审议情况 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： （一） 审议通过《关于审议公司 2025 年半年度报告及其摘要的议案》 本议案经第二届董事会审计委员会第十九次会议审议通过后提交董事会。具 体内容详 ...

Meeting Overview - The second meeting of the Supervisory Board of Chengdu XianDao Pharmaceutical Development Co., Ltd. was held on August 26, 2025, with all three supervisors present [1] - The meeting was convened in accordance with relevant laws and regulations, and the resolutions passed were deemed legal and effective [1] Resolutions Passed - The Supervisory Board approved the company's 2025 semi-annual report and its summary [2] - The board also approved the special report on the storage and actual use of the raised funds for the first half of 2025 [2] - A resolution was passed to cancel the Supervisory Board, amend the company’s articles of association, and remove the chairman of the Supervisory Board, pending approval from the shareholders' meeting [2][3] - The board approved the draft of the 2025 restricted stock incentive plan and its summary, which will also be submitted for shareholder approval [3] - The implementation assessment management measures for the 2025 restricted stock incentive plan were approved, pending shareholder approval [3] - The verification of the list of incentive objects for the 2025 restricted stock incentive plan was also approved [3] - The draft of the 2025 employee stock ownership plan and its summary could not be resolved due to two supervisors abstaining from voting, and it will be submitted for shareholder approval [4] - The management measures for the 2025 employee stock ownership plan could not be resolved for the same reason and will also be submitted for shareholder approval [4]

Core Viewpoint - The Shenzhen BGI Genomics Co., Ltd. is holding its third extraordinary general meeting of shareholders in 2025 to discuss and vote on several key proposals, including amendments to the 2024 restricted stock incentive plan and the employee stock ownership plan, aimed at enhancing employee motivation and aligning interests with shareholders [5][22]. Group 1: Meeting Procedures - The meeting will ensure the legal rights of all shareholders and maintain order and efficiency, following relevant laws and regulations [1][2]. - Attendees must register and confirm their participation before the meeting starts, as latecomers will not be allowed to vote [2][3]. - The meeting will follow a predetermined agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3][4]. Group 2: Proposals and Amendments - Proposal One involves the revision of the 2024 restricted stock incentive plan, which aims to enhance performance assessment indicators at the company level [7][9]. - The revision is driven by the need to adapt to external market changes and to focus on increasing market share in the gene sequencing equipment sector, which is crucial for future revenue growth [9][10]. - Proposal Two addresses the amendments to the 2024 employee stock ownership plan, which also includes new performance assessment indicators to improve governance and employee engagement [16][17]. Group 3: Performance Assessment Criteria - The performance assessment for the incentive plans will be based on revenue growth rates, excluding impacts from public health events, with specific targets set for 2024 and 2025 [9][19]. - The revised criteria will include metrics related to gene sequencing equipment sales, emphasizing the importance of capturing market share to secure long-term customer value [10][18]. - The company aims to ensure that the revised performance targets remain challenging yet achievable, fostering a sustainable growth environment [20][21].

Investment Rating - The investment rating for the company is "Buy" [17] Core Views - The company achieved record high performance in Q2 2025, with revenue of 4.177 billion yuan, up 7.71% year-on-year, and a net profit of 313 million yuan, up 12.34% year-on-year [2][3] - The company is actively expanding its global presence, with overseas revenue growing by 27.21% year-on-year, contributing to 35.84% of total revenue [3] - The company has implemented an employee stock ownership plan to ensure stable growth, with performance targets set for net profit growth from 2025 to 2027 [4] Financial Performance - In H1 2025, the company reported revenue of 7.876 billion yuan, a year-on-year increase of 7.1%, and a net profit of 554 million yuan, up 11.42% year-on-year [2][3] - The gross profit margin for H1 2025 was 22.77%, with a net profit margin of 6.8% [4] - The company plans to distribute a cash dividend of 390 million yuan, representing 70.2% of its net profit for the period [4] Revenue Breakdown - Revenue from various product segments in H1 2025 included 5.461 billion yuan from paper packaging, 1.297 billion yuan from packaging accessories, 584 million yuan from eco-friendly paper-plastic products, and 379 million yuan from other products [3] - Domestic revenue decreased by 1.59% to 5.053 billion yuan, while overseas revenue increased by 27.21% to 2.823 billion yuan [3] Future Projections - Revenue projections for 2025 to 2027 are 19.129 billion yuan, 21.410 billion yuan, and 23.547 billion yuan, respectively, with year-on-year growth rates of 11%, 12%, and 10% [4] - Net profit projections for the same period are 1.637 billion yuan, 1.814 billion yuan, and 2.077 billion yuan, with year-on-year growth rates of 16%, 11%, and 14% [4]

随半年报一起发布的，还有威派格正式推出覆盖董事、监事、高管及核心骨干员工的员工持股计划。该 计划总募集资金不超过3,681.04万元，对应股份不超过1,034万股，约占公司总股本1.81%。标的股份全 部来自公司已回购的股票，认购价格为3.56元/股，大幅低于市场均价，体现出公司对核心人才的激励 决心。 与单纯的激励工具不同，该计划的锁定期最长60个月，设置了"分期解锁+业绩考核"的约束机制。员工 所认购的股份需在12个月、24个月和36个月分三批解锁，解锁比例分别为40%、30%、30%。同时，解 锁条件与公司未来三年的业绩目标紧密挂钩，在2025年至2027年间，公司净利润与营业收入各不低于 0.30/1.00/2.00亿元与13.00/15.60/18.72亿元的情况下，视作公司整体业绩目标达成，且个人考核合格， 员工才能分批次解锁所持股份，实现与企业经营成果的真正共赢。 具体来看，威派格2025年上半年经营性现金流净额为-7,762万元，得益于应收账款清收力度的持续加 大，较同期-3.04亿元的数据，大幅改善超过2.2亿元。报告期内，公司回款金额同比增加0.42亿元，其 中2024年及以前年度形成的应 ...

Core Viewpoint - Shanghai Zhezhong Group Co., Ltd. has completed the non-trading transfer of its first employee stock ownership plan, which involves the transfer of shares sourced from the company's repurchased stock [1][2][3] Group 1: Employee Stock Ownership Plan Details - The employee stock ownership plan was approved during the board meeting on July 18, 2025, and the first extraordinary shareholders' meeting on August 4, 2025 [1] - The plan aims to raise a maximum of 73.127125 million yuan, with each unit priced at 1 yuan, totaling 73,127,125 units [5][6] - A total of 100 individuals, including supervisors and core employees, participated in the plan, with the actual subscription amounting to 73,127,125 yuan [5][6] Group 2: Share Repurchase and Transfer - The company repurchased a total of 5,750,060 shares for 100.0076 million yuan from August 27, 2021, to August 31, 2022, and an additional 22,100,110 shares for approximately 241.477 million yuan from November 28, 2024, to August 2, 2025 [2][3] - The non-trading transfer of 5,850,170 shares to the employee stock ownership plan was completed on August 25, 2025, representing 1.32% of the company's total share capital, at a price of 12.50 yuan per share [6][7] Group 3: Governance and Accounting - The employee stock ownership plan does not have any related party relationships with the company's controlling shareholders or management, ensuring independence in decision-making [8] - The plan's duration is set for 60 months, with vesting periods at 12, 24, and 36 months based on performance assessments [7] - The company will follow the accounting standards for equity-settled share-based payments, with impacts on financial results to be confirmed by annual audit reports [9]

| 关于湖北久量股份有限公司 | | | | | | | --- | --- | --- | --- | --- | --- | | 终止第一期员工持股计划的 | | | | | | | 法律意见书 | | | | | | | 二〇二五年八月 | | | | | | | 广东君信经纶君厚律师事务所 | | | | | 法律意见书 | | 目 录 | | | | | | | 广东君信经纶君厚律师事务所 | | | | 法律意见书 | | | 释 | | 义 | | | | | 在本《法律意见书》中，下列简称仅具有如下特定含义： | | | | | | | 久量股份、本公司、公 | | | 湖北久量股份有限公司（原名称为"广东久量股份有限公 | | | | 指 | | | | | | | 司"） | 司 | | | | | | 中国证监会 中国证券监督管理委员会 | 指 | | | | | | 《公司法》 《中华人民共和国公司法》 | 指 | | | | | | 《证券法》 《中华人民共和国证券法》 | 指 | | | | | | 《关于上市公司实施员工持股计划试点的指导意见》（中国 | | | | | | | ...